Data completeness
0/8 — Limited
Drug data last refreshed 2w ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NYSTAFORM is a topical ointment combining clioquinol and nystatin for dermatological use. This fixed-dose combination targets fungal and bacterial skin infections through dual antimicrobial mechanisms. The product is in pre-launch stage under sponsor R-Pharm US.
Pre-Launch
Pre-launch stage indicates early commercialization phase; team building and launch planning are active priorities.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on NYSTAFORM offers early-stage launch career opportunity with R-Pharm US, a mid-size generic and specialty pharma company. The pre-launch phase typically requires cross-functional focus on regulatory clearance, pricing strategy, and market preparation.
Brand ManagerField Sales Representative
Worked on NYSTAFORM at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.